



Clinical Trial and Consulting Services

July Newsletter



Where Life-changing Therapies Turn First

Volume 11, Issue 7

We are recruiting for CRAs in the US, UK, France, Belgium, Sweden, Germany, Poland, Italy and the Netherlands!

If you are interested in scheduling a meeting with CTI, please contact Nick Schatzman at 513-598-9290 or via email at nschatzman@ctifacts.com

Upcoming Medical Meetings CTI will be Attending ...

MSC 2013
Cleveland, Oh
August 19 – 21, 2013

Employee Update

Congratulations to the following CTI employees recently promoted:

Dr. William Aronstein – Vice President, Medical Affairs

Kevin Wesley – Clinical Data Associate II

S² STATISTICAL SOLUTIONS COMBINING FORCES WITH CTI

S² Statistical Solutions (S²) is a consulting firm that performs outcomes research and analytics, data mining, economic evaluations, dynamic data visualizations, and systematic literature reviews for pharmaceutical, diagnostic and medical device companies. Founded by Candace Gunnarsson, PhD, in 2003 **S² specializes in generating and interpreting evidence from large scale claims and hospital databases for real world clinical outcomes and economic evaluations.** Evidence is typically presented in the most effective and high-impact venues, including peer-reviewed publications and industry-related conferences, and S²'s studies have been published in over 100 peer-reviewed journals. The team of experts includes statisticians, epidemiologists, engineers, software developers and computer programmers, in addition to having consulting relationships with various academic health economists and medical professionals.

The services that S² offers include but are not limited to economic evaluations, which may be important in the development of clinical programs, as well as valuations to assist in pricing considerations. S²'s experience with systematic review and meta analysis along with large scale databases can assist in the development of endpoints and identification of patient populations based on proposed inclusion and exclusion criteria for clinical trial design.

S² is excited to join CTI and believes S² and CTI principles, work ethic and expertise complement one another. CTI has been very welcoming and instrumental in merging the two companies together. An economic research summit was held in Philadelphia with S² and CTI for the objective of exploring opportunities to integrate economic outcomes research and evaluations into the clinical trial work. In attendance were S²'s health economic academic affiliates: Guy David, PhD- Assistant Professor, Health Care Management Department, Wharton School of Business, University of Pennsylvania; John Rizzo, PhD- Professor of Economics, Cardiology and

Please welcome the newest additions to CTI:

Jacqueline Miefert – Senior Study Coordinator

John Green – Senior Systems Administrator

Julia Reuter – Clinical Research Associate, Germany

Tricia Robinson – Senior Clinical Data Associate

David Vessey – Siebel Clinical Administrator

Grace Baker – Senior Regulatory Specialist

Quick Links...

[CTI in the news](#)

[Our Website](#)

[Email](#)

[Join Our Mailing List!](#)

Preventive Medicine Departments of Economics and Medicine, Stony Brook University; Lorens Helmchen, PhD- Associate Professor, Department of Health Administration and Policy, George Mason University. S² and CTI are on track to achieve great things together.

For more information, please contact:

Lynn Fallon - President, Consulting and Executive Vice President, CTI Clinical Trial and Consulting Services

513.598.9290

lfallon@ctifacts.com

www.ctifacts.com

Candace Gunnarsson, PhD, - President, S² Statistical Solutions, Inc.

513.247.0561

candaceg@s2stats.com

www.s2stats.com

About CTI

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI's focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program's success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.